Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Luke who wrote (631)	5/14/1998 2:00:00 AM
From: Rocketman	Read Replies (1) \| Respond to of 3202

While I'm not sure of the exact way the deals are written, keep in mind that the companies that have contracted with INCY to use their information have a contractual obligation to INCY, not an obligation based on patents. INCY must have a way of dealing with issues relating to getting a royalty from things such as using their clones to develop gene targets that are used to identify a drug through screening processes. This is definitely a good question to approach management with. This patent fee issue could make patenting ESTs incredibly expensive if you have to patent in groups of 10 sequences. Makes trade secret status seem desirable. Good question for my patent friends! Rman